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Research on embryonic stem cells has generated great intrigue in the scientific 
community.  Many medical researchers consider stem cell-based therapies to have the 
potential of treating a host of human ailments and yielding a number of medical benefits.  
They are motivated by the possibility of treating incurable diseases or facilitating 
effective treatment methods.  Their enthusiasm is shared by many of those who are 
afflicted with these debilitating diseases.  
However, the methodology of this research raises numerous ethical and public 
policy concerns.  The extraction of embryonic stem cells for research destroys the human 
embryo.  This has generated a storm of debate about if, and in what circumstances, this 
research can be legally and ethically justified.  The concerns are heightened further when 
embryos are created specifically for use in the very research that occasions their 
destruction.  In response, numerous countries have passed legislation that attempts to 
control some of the more controversial aspects of embryonic stem cell research.  For 
example, in May 2002, Canada introduced draft legislation that would govern and restrict 
a number of practices related to this fast-growing field of research. 
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Assessing the legality of embryonic stem cell research, and whether there are any 
justifications to restricting this field, raises a number of challenging questions.  What is 
the legal status of the unimplanted embryo?  Is there a societal interest in protecting 
embryos from such research?  If so, what legal balance is required when legislating in 
relation to embryos, given the potential medical benefits of stem cell research?  These 
questions, and the broader legal debate surrounding stem cell research, will be the focus 
of this paper. 
Part I. The Science of Embryonic Stem Cell Research 
A. The Basics of Human Reproduction 
Understanding what embryonic stem cells are and why they are so valuable for 
research requires a short primer on the basics of human reproduction.  The human 
embryo has its origins in specialized gamete cells, known as the spermatozoon for males 
and the ovum for females.2 Each gamete contains a set of 23 chromosomes, out of the 46 
that comprise the entire human genome.3 Chromosomes contain highly condensed DNA, 
short sequences which make up the genes that code for the synthesis of the different 
proteins that construct the human body.4 The chromosomes are enclosed within a cellular 
organelle that in gametes are known as pronuclei.  Conception arises upon the union of 
two gametes.  The two pronuclei fuse, and a single cell known as a zygote is created.5 
This zygote contains a total of 46 chromosomes, half from each parent, and is therefore 
complete with the entire genetic makeup needed to direct the development of a 
genetically distinct human being.  
                                                 
2 See, e.g. Bruce Alberts et al., Essential Cell Biology:  An Introduction to the Molecular Biology of the 
Cell 305 (1998). 
3 See, e.g. Anthony J.F. Griffiths et al., An Introduction to Genetic Analysis 2 (4th ed. 1989). 
4 See, e.g. Alberts et al., supra note 1, at 246-7. 
5  See, e.g. Alberts et al., supra note 1, at 306. 
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The zygote then undergoes a series of cell divisions known as cleavages, where 
the dividing cells, known as blastomeres, double in number following each cleavage 
event.6 By the time the zygote has divided into sixteen cells, it is comprised of a compact 
sphere of blastomeres known as a morula.  After five to seven days, it has developed into 
a blastocyst, at which stage a cavity has formed within the structure and two distinct cell 
types can be distinguished:  a peripheral cellular layer known as a trophoblast, and an 
inner cell mass.7 The trophoblast is destined to give rise to the placenta, which will 
nourish the embryo as it develops within its mother.  In contrast, the inner cell mass will 
develop into the embryo, the fetus and eventually the fully developed child. 
At about 14 days following conception, a structure within the inner cell mass 
known as the primitive streak is formed.8 The primitive streak marks the longitudinal 
head-to-tail axis of the future embryo.  This is what gives rise to an individual human’s 
bilateral symmetry.  The major organs of the body eventually differentiate along this axis, 
with tissue to the left and right of the streak developing into the left and right sides of the 
body, respectively.9 The appearance of the primitive streak is widely regarded as a 
fundamental step in embryonic development, the significance of which will be discussed 
later in this paper.10 By the time the main organs develop, usually eight weeks following 
conception, the embryo is scientifically termed a fetus.11 This terminology should be 
                                                 
6  See generally William J. Larsen, HUMAN EMBRYOLOGY, (3rd ed. 2001) (overview of the sequence of cell 
divisions following fertilization). 
7 See, e.g. David F. Moffett et al., HUMAN PHYSIOLOGY:  FOUNDATIONS & FRONTIERS 728 (2d ed. 1993). 
8 Kevin U. Stephens, Sr., Reproductive Capacity:  What Does The Embryo Get? 24 S.U.L. REV. 263, 267 
(1997). 
9 Kayhan Parsi, Metaphorical Imagination:  The Moral and Legal Status of Fetuses and Embryos, 2 
DEPAUL J. HEALTH CARE L. 703, 753 (1999). 
10 See, e.g. J. Marshall, The Case Against Experimentation in G. Basen, M. Eichler, A. Lippman, eds., 
MISCONCEPTIONS 2:  THE SOCIAL CONSTRUCTION OF CHOICE AND THE NEW REPRODUCTIVE AND GENETIC 
TECHNOLOGIES 111 (1994). 
11 See, e.g. Michael Abercrombie et al., THE PENGUIN DICTIONARY OF BIOLOGY 113 (6th ed. 1977). 
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distinguished from that used in Canadian courts, which commonly refer to the unborn 
child at any stage of development as a fetus.  
  B. Human Reproduction and Stem Cells 
 The early embryo is comprised of stem cells.  These can be characterized as those 
precursor cells, not yet specialized, that give rise to the more specialized cells of the 
human body.12 The biological process by which cells specialize is known as 
differentiation.  It occurs when some of the approximately 80,000 genes in the 
chromosomes of a cell are inactivated, while the remaining genes are selectively 
expressed.13 The function of specific cells in the body will depend on which of these 
genes are selected for expression.  Incidentally, each cell retains the full complement of 
the DNA that makes up the human genome throughout the differentiation process.  It is 
for this reason that a specialized cell from an adult body can theoretically be used to 
clone an entire human. 
 Stem cells can be subdivided into three main categories, depending on their level of 
differentiation:  totipotent, pluripotent and monopotent stem cells.14 The least 
differentiated, totipotent stem cells, have unlimited developmental capacity (i.e. the 
potential to produce an entire human).  Thus, the initial single-celled zygote described 
above is totipotent.  In contrast, the inner cell mass of the blastocyst is comprised of 
pluripotent stem cells, which are more highly differentiated but can potentially specialize 
into almost any type of tissue.  These cells specialize further into monopotent stem cells, 
which serve as the precursors of specific cell-types having particular functions.  They 
                                                 
12 See, e.g. Moffett et al., supra note 6, at 10. 
13 See generally Griffiths et al., supra note 2, at 572-605 (discussion on the processes of cell 
differentiation). 
14 U.S.A., NATIONAL INSTITUTES OF HEALTH, STEM CELLS:  A PRIMER (May 2000) [hereinafter STEM 
CELLS].  
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include blood stem cells, skin stem cells and stem cells of any of the 214 such cell-types 
of the human body.15 It is these pluripotent and monopotent stem cells that researchers 
hope to isolate, culture and one day apply to therapeutic ends.  
  C. Stem Cells and In Vitro Fertilization 
   While the developmental stages outlined above typically occur in the female 
womb following coitus, the embryos used in embryonic stem cell research are created 
asexually via in vitro fertilization (IVF).  This procedure was first developed for humans 
in the late 1970s to assist infertile couples with having children.  The first step in the 
process requires obtaining human eggs from a female donor, who has usually been 
treated with drugs that induce the maturation of multiple follicles in her ovaries.16 This 
increases the yield from a single ovulation cycle from one egg to as many as a few dozen 
eggs per month.  The eggs are retrieved either surgically, or by suction through a process 
known as ultrasound-guided transvaginal aspiration.17 The eggs are then artificially 
fertilized in a petri dish with donated sperm. 
  Biotechnology, through a process known as cryopreservation, now enables the 
freezing and storage of these artificially created embryos for future use, such as in 
fertility treatments.  The embryos are first treated with a cryoprotectant solution to 
replace the water in the cells (which would otherwise expand upon freezing, leading to 
cell rupture).18 They are then gradually cooled and transferred to liquid nitrogen, where 
they are stored at a temperature of minus 195 degrees Centigrade. They are then 
                                                 
15 Id. 
16 Carl H. Coleman, Procreative Liberty and Contemporaneous Choice:  An Inalienable Rights Approach 
to Frozen Embryo Disputes, 84 MINN. L. REV. 55, 58 (1999). 
17 Luigi Brandimarte, Comment, Sperm Plus Egg Equals One “Boiled” Debate:  Kass v. Kass and the Fate 
of the Frozen Pre-Zygotes (2000) 17 N.Y.L. SCH. J. HUM. RTS. 767, 771 (2000). 
18 Coleman, supra note 15, at 60. 
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gradually cooled and transferred to liquid nitrogen, where they are stored at a temperature 
of minus 195 degrees Centigrade.19 The cryopreservation process is a cheaper, easier and 
more time efficient method of obtaining future embryos than repeating the IVF 
procedure. 
 D. The Medical Potential of Stem Cells  
In vitro fertilization and cryopreservation have provided researchers with a 
convenient way of obtaining embryos that can supply stem cells for research goals.  
Human embryonic stem cells were first isolated in November 1998 by James A. 
Thompson of the University of Wisconsin, and John D. Gearhart of Johns Hopkins 
University.20 They have since been successfully induced to self-replicate for mass 
production.21 Thus, cultures of desired stem cell lines can be established for widespread 
potential medical application. 
Research on stem cells has many benefits over research on other types of cells.  
For example, cultures of adult cells traditionally do not last very long and new cell 
cultures are constantly needed to replace old ones.22 This has been partly attributed to the 
role played by chromosomal structures known as telomeres.  Telomeres exist at the ends 
of chromosomes and function as protective caps.23 They normally shorten with each 
replication of the chromosome (i.e. after every cell division cycle), a fact that is thought 
to contribute to the aging process.  In the rapidly dividing stem cells of the embryo, 
however, there is a high expression of an enzyme known as telomerase, which helps 
                                                 
19 Brandimarte, supra note 16, at 773. 
20 James A. Thompson et al., Embryonic Stem Cell Lines Derived From Human Blastocysts, 282 SCIENCE 
1145 (1998). 
21 Gregg Easterbrook, Will Homo sapiens become obsolete?, NEW REPUBLIC (March 1, 1999), at 20. 
22 Jason H. Casell, Lengthening the Stem: Allowing Federally Funded Researchers to Derive Human 
Pluripotent Stem Cells from Embryos,34 U. MICH. J.L. REFORM 547, 551-552 (2002). 
23 See, e.g. Alberts et al., supra note 1, at 249. 
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prevent telomeres from shortening.24 Thus, cultures of desired embryonic stem cell lines 
could, at least theoretically, be capable of indefinite reproduction.  This would make them 
ideal subjects of manipulation in medical research. 
One of the potential medical applications of stem cells is in a procedure known as 
cell therapy, where stem cells are directly injected into the human body.25 While the exact 
mechanisms are not yet clear, such cells are often able to target their corresponding organ 
or tissue types.  In one experiment, for example, pig liver stem cells that were injected 
into humans were able to target the human liver.26 In another experiment, mice that had 
suffered from heart attacks were injected with blood stem cells.27 The cells migrated to 
the damaged regions of the heart, and even produced vessels to supply the new heart 
muscle with blood.  Stem cells have also been shown to develop into brain tissue when 
injected into rats that had suffered stroke-related brain damage.28  
Another exciting potential application of stem cell therapy is in the treatment of 
spinal injuries.  Experiments at John Hopkins University have shown that some rats that 
had pluripotent stem cells injected into their spinal fluid regained partial leg movement.29 
Clearly, there is hope that the same success can be attained with paralyzed humans.  Cell 
therapy is also an especially effective medical treatment because it utilizes the body’s 
own curative abilities.  This helps side-step some of the problems associated with 
transplantation, such as organ rejection.  
                                                 
24 Id. at 250.    
25 Khristan A. Heagle, Should There be Another Ewe?  A Critical Analysis of the European Union Cloning 
Legislation, 17 DICK. J. INTL L. 135 (1998). 
26 Id. 
27 Stem cells repair heart attack damage,  (March 31, 2001), at 
http://www.news.bbc.co.uk/hi/health/1251876.stm (date last visited April 2001). 
28 Stem cells repair stroke damage, (Feb. 17, 2001), at http://www.news.bbc.co.uk/hi/health/1174232.stm 
(date last visited March, 2001). 
29 Jonathan Knight et al., Reach for the Prize, NEW SCIENTIST (Nov. 18, 2000), at 11. 
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  E. Possible Applications of Stem Cell Technology 
 Stem cells can also have much more specific medical applications.  By identifying 
and administering the correct growth factors, scientists hope to someday be able to direct 
stem cells to differentiate along a specific path into desired cell or tissue types.  These 
can then be transplanted into patients suffering from various physical ailments.  In this 
way, it is hoped that embryonic stem cell research can provide treatments for a number of 
diseases. 
 Diabetes, for example, results when the immune system self-destroys pancreas cells 
that produce the insulin hormone.30 Insulin is essential in maintaining blood sugar levels 
at a safe concentration.  While insulin injections are available to diabetes sufferers, they 
are painful and need to be administered constantly to sustain life.  A much more effective 
treatment would be to derive insulin-producing cells from pancreatic stem cells and 
directly transplant such cells into patients.  The research looks promising.  Scientists at 
the National Institutes of Health, for example, have successfully used the embryonic stem 
cells of mice to derive cells that express insulin and other pancreatic hormones in diabetic 
mice.31  
Other diseases that stem cell research may help alleviate include Parkinson’s, 
Alzheimer’s and Huntington’s disease.  In each of these neurological diseases, there is a 
loss of neurons from a particular region of the brain.32 Stem cell technology may help 
replace these lost neurons with ones cultured from brain stem cells. Still another possible 
candidate for stem cell therapy is DiGeorge’s Syndrome.  This disease is characterized by 
                                                 
30 Robert Berkow, ed., THE MERCK MANUAL OF DIAGNOSIS AND THERAPY 1037 (1982) [hereinafter MERCK 
MANUAL]. 
31 Casell, supra note 21, at 554. 
32 See generally MERCK MANUAL, supra note 29.  
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the absence of immune cells in the thymus gland, increasing the patient’s susceptibility to 
serious infections at an early age.33 Again, the missing immune cells can be replaced by 
ones derived from precursor stem cells. One last example is leukemia and other blood 
diseases for which treatment may be found in blood stem cells.  Similar stem cell 
therapies potentially exist for a number of other cell-based illnesses.  
There is a wide array of other potential medical uses of stem cells.  For example, 
stem cells may be able to yield cells that can help treat malignant tumors (which are 
created by cells that divide uncontrollably), or to provide cells that can generate bone 
marrow for chemotherapy patients.34  Stem cell technology may even progress to a level 
where human organs can be directly grown for transplantation.  This would help alleviate 
the severe shortage of donated organs that exists in Canada and in most parts of the 
world.35 Moreover, if therapeutic stem cells are derived from embryos that are cloned 
from a patient, they will serve as a perfect genetic match for recipients, thus overcoming 
the problems of immune rejection.  
There are also more general benefits to embryonic stem cell research.  First, it can 
yield answers to the complex events that characterize human development, as well as to 
the root causes of various diseases and genetic disorders.36 Second, it can help improve 
medications, through the creation of cell types that can serve as subjects for tests seeking 
to determine which drugs are safe and beneficial for human use.37 Isolating human 
                                                 
33 Jose L. Gonzalez, The Legitimization of Fetal Tissue Transplantation Research Under Roe v. Wade, 34 
CREIGHTON L. REV. 895, 908-909 (2001). 
34 Michael J. McDaniel, Legal Perspectives on Cloning: Regulation of Human Cloning:  Implications for 
Biotechnological Advancement, 32 VAL. U.L. REV. 543, 553 (1998). 
35 Id. at 558. 
36 Department of Health and Human Services, Public Health Service, National Institutes of Health, Draft 
National Institutes of Health Guidelines for Research Involving Human Pluripotent Stem Cells, at 
http://www.nih.gov/news/stemcell/draftguidelines.htm (December 1999). 
37 Id. 
9  
embryonic stem cells, however, necessitates the destruction of a human embryo.  This 
raises a host of legal and policy issues, a discussion of which will be the focus of the 
remainder of this paper. 
 
Part II. The Legal Status of the Embryo 
  A. The Existing Jurisprudence on Prenatal Rights 
The jurisprudence pertaining to the rights of the embryo or fetus in Canada fairly 
clearly outlines the legal status of the unborn child.  That legal status was concisely 
summarized by the Supreme Court of Canada in Winnipeg Child and Family Services 
(Northwest Area) v. G.(D.F.).: 
The position is clear.  Neither the common law nor the civil law of 
Quebec recognizes the unborn child as a legal person possessing 
rights. This principle applies generally, whether the case falls under 
the rubric of family law, succession law or tort.  Any right or interest 
the foetus may have remains inchoate and incomplete until the birth of 
the child.38
  
As the Court indicates, this principle has held true in all areas of law.  In looking 
at criminal law, abortion has historically been allowed for various reasons, such as to 
protect the mother’s health.  Thus, in this example, it is apparent that the unborn child has 
not always held full rights as a person.  In R. v. Morgentaler,39 the Supreme Court of 
Canada found that the abortion-access provisions of the Criminal Code unduly infringed 
upon the constitutional rights of pregnant women.  Additionally, in R. v. Sullivan,40 the 
Canadian Supreme Court held that “person” in the criminal negligence provisions of the 
                                                 
38 Winnipeg Child and Family Services (Northwest Area) v. G.(D.F.), [1997] 3 S.C.R. 925 [hereinafter 
Winnipeg] at ¶ 15. 
39 R. v. Morgentaler, [1988] 1 S.C.R. 30 [hereinafter Morgentaler]. 
40 R. v. Sullivan and Lemay, [1991] 1 S.C.R. 489. 
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Criminal Code held the same meaning as “human being,” which the Code defines as a 
child that “has completely proceeded, in a living state, from the body of its mother.”41  
     A civil law analysis leads to similar conclusions.  In tort law, the Canadian Supreme 
Court recognized as early as 1933 in Montreal Tramways Co. v. Leveille42 that there is a 
right or duty in tort owed by third persons to an unborn child.  Any right of civil action, 
however, is contingent upon the child being born alive.  Similarly, an analysis of estate 
and property law reveals no instance where property was passed to the heirs of a stillborn 
or aborted fetus.  Furthermore, the Saskatchewan Court of Appeal in Borowski v. Canada 
(Attorney General) concluded generally that “there are no cases in Anglo-Canadian law 
giving the foetus qua foetus status.”43 It should be noted that some Canadian legislation, 
primarily in the area of family law, does include unborn children within its definition of 
“child.”44 Some courts have also found that a fetus is a “child” for purposes of some 
family law legislation.45 However, other courts have reached precisely the opposite 
conclusion.46  
Nor has the fetus ever been constitutionally recognized as a person under the 
Charter of Rights and Freedoms.  Two Ontario courts have found that fetuses are not 
persons under the Charter.47 In Borowski, the plaintiff argued that the therapeutic abortion 
provisions of the Criminal Code were in violation of the constitutional rights of the 
                                                 
41 Criminal Code, R.S.C. ch. C-46, § 223(1)(1985)(Can.). 
42 Montreal Tramways Co. v. Leveille, [1933] S.C.R. 456. 
43 Borowski v. Canada (Attorney General) 33 C.C.C. (3d) 402. 
44 See, e.g. the New Brunswick Family Services Act, where an "unborn child" is included within the 
definition of “child”:  Family Services Act, S.N.B. 1980, ch. F-2.2, § 1(g)(a)(1980)(Can.) at 
http://www.gnb.ca/acts/acts/f-02-2.htm. 
45 See, e.g. Re Children's Aid Society of City of Belleville and T, [1987] 59 O.R. (2d) 204, and Re 
Children's Aid Society for the District of Kenora and J.L. [1981] 134 D.L.R. (3d) 249. 
46 See, e.g. Re Baby R , 53 D.L.R. (45h) 69 (B.C.S.C. 1988), and New Brunswick v. N.H., 224 N.B.R. (2d) 
80 (1996). 
47 See, e.g. R. v. L.(N.), 10 W.C.B. (2d) 582 (1990), and Campbell v. Attorney-Gen. of Ont., 58 O.R. (2d) 
209 (1987). 
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foetus.  However, the Saskatchewan Court of Appeal concluded that a fetus is not 
included within the definition of “everyone” in section 7, or “every individual” in section 
15 of the Charter.  A subsequent appeal to the Canadian Supreme Court was declined on 
the grounds of mootness, resulting from the striking down of all abortion provisions in 
the Criminal Code in Morgentaler, supra.   
 B. The Special  Circumstances of In Vitro Embryos 
The law pertaining the legal status of unborn children in Canada appears to be 
fairly settled.  However, there is still no clear indication as to what rights, if any, an 
embryo might have as an independent entity (for instance, when it exists in an in vitro 
state).  The cases discussed above are not as helpful in this regard.  They comment only 
about the rights of unborn children who exist not as independent entities but as a 
biological part of their mothers.  This fact presents a crucial contextual difference.  Its 
significance with respect to female equality rights has been recognized by courts on 
numerous occasions.  According to the Canadian Supreme Court in Winnipeg “[t]he 
potential for intrusions on a woman's right to make choices concerning herself is 
considerable.  The foetus' complete physical existence is dependent on the body of the 
woman.  As a result, any intervention to further the foetus' interests will necessarily 
implicate, and possibly conflict with the mother's interests.”48 The special nature of the 
maternal-fetal relationship that courts pay deference to is fundamentally different from 
that existing between the embryo or fetus and a third party.   
This point was made clear in Dobson v. Dobson.49 In Dobson, a tort action had 
been brought on behalf of a child for prenatal injuries it had suffered due to the allegedly 
                                                 
48 Winnipeg, supra note 37, at ¶ 37. 
49 Dobson v. Dobson, 2 S.C.R. 753 (Sup.Ct.Can. 1999) at ¶ 29. 
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negligent acts of its mother.  In ruling in favor of the mother, the Canadian Supreme 
Court pointed out that “it is the biology of the human race which decrees that a pregnant 
woman must stand in a uniquely different situation to her fetus than any third-party.”50  
Hence, it is unclear how to apply the principles derived from these cases to help 
define the legal status of the embryo in the special context of stem cell research.  The 
jurisprudence has generated rules relating to unborn children.  The problem, of course, is 
that this birth event cannot even be contemplated in the case of the unimplanted, in vitro 
embryos.  With in vitro embryos, the complex physical and intensely personal 
relationship between the embryo and its mother that courts have frequently alluded to is 
absent.  Any legal relationships that exist are essentially only between the embryos and 
third parties. 
This conclusion suggests that the common law rules are rather lacking in 
providing guidance on those special situations created by artificial reproductive 
technologies and associated practices such as stem cell research.  There is, therefore, a 
need to elucidate a different standard regarding the legal status of in vitro embryos.  This 
standard will need to address the unique and largely unprecedented circumstances that 
characterize research on unimplanted embryos.  It will also need to contemplate the 
indirect impact that conferring specific embryonic rights (in any context) may have on 
women's reproductive autonomy. 
C. A Legislative Role in Protecting the Embryo 
It will be the role of the legislators to determine the standard that ought to be applied 
to in vitro embryos.  Courts have already suggested that Parliament has a legitimate role 
in conferring legal protections upon the embryo in clearly specified contexts.  In 
                                                 
50 Id. 
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Winnipeg, the Canadian Supreme Court stated that “if Parliament or the legislatures wish 
to legislate legal rights for unborn children or other protective measures, that is open to 
them, subject to any limitations imposed by the Constitution of Canada.”51  
And in Morgentaler, Justice Dickson found for the majority that the protection of the 
fetus would be a sufficiently important legislative objective under section one of the 
Charter.  The Court was itself reluctant in Winnipeg, supra, to define specific prenatal 
rights.  To do so, it feared, would place the courts “at the web of thorny moral and social 
issues which are better dealt with by elected legislators than by the courts […since] the 
courts would find it difficult to limit application of the new principle to particular 
cases.”52  
Lower courts had earlier already recognized a legislative role in protecting the 
embryo/fetus.  Perhaps most tellingly, in Borowski v. Attorney General of Canada et al., 
Matheson J. of the Saskatchewan Court of Queen’s Bench stated that “although rapid 
advances in medical science may make it socially desirable that some legal status be 
extended to fetuses, irrespective of ultimate liability, it is the prerogative of Parliament, 
and not the courts, to enact […the appropriate] legislation.”53 Thus, some courts seem to 
have already recognized a role for Parliament to legislate the use of embryos in such 
medical sciences such as stem cell research. 
  It is important to remember that the “particular cases” referred to in Winnipeg, 
supra, where Parliament may legislate, pertain to “unborn children” – a state, again, 
outside the context of stem cell research.  However, each in vitro embryo is one that may 
potentially be implanted and turned into an unborn child, bringing it within the scope of 
                                                 
51 Winnipeg, supra note 37, at ¶ 12. 
52 Winnipeg, supra note 37, at ¶ 24. 
53 Borowski v. Attorney Gen. of Can., 4 D.L.R. (4th) 112 (1983). 
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the traditional prenatal legal analysis.  Moreover, having already recognized in Winnipeg, 
supra, that legislators may further explicate prenatal rights, courts may also accept 
extending this legislative role into the realm of protecting young, in vitro embryos, 
subject to any limitations imposed by the Charter.  To do so, however, will require a clear 
elucidation of the bases upon which legislative protections for the embryo can be 
justified.  It will also require a balancing of the different, overlapping social interests that 
arise in that context. 
Part III. Legislating Embryonic Stem Cell Research 
 A. General Legislative Considerations 
A number of jurisdictions have introduced legislation that seeks to protect the in 
vitro embryo.  In the United States, for example, several states including Massachusetts, 
Minnesota, North Dakota, Rhode Island and Louisiana have enacted laws that provide 
protections to embryos that exist outside the womb, such as prohibitions on embryo 
experimentation.54 In Canada, legislation pertaining to this field was tabled in Parliament 
in May 2002. 
It is essential for any future legislation to carefully balance the numerous and 
often conflicting social considerations that are implicated in the context of stem cell 
research.  For example, it may be a purported threat to human dignity that serves as the 
basis for legislation that restricts various forms of embryo research.  Indeed, the 2001 
report of the Standing Committee on Health, discussed further in section VI below, 
recommends that an overarching consideration of “respect for human individuality, 
dignity and integrity” be included in a statutory declaration for forthcoming legislation on 
                                                 
54 See M.S.A. § 145.421 (West 1989); M.G.L.A. 112 § 12J(a)(I)(West 1996); N.D.C.C. 14-02.2-
01(1)(3)(West 1991); R.I.S.T. § 11-54-1(c) (West 1994). 
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genetic technologies.55 Such a consideration will need to be balanced against the potential 
medical benefits that stem cell research may provide. 
  A better legislative approach may be to make in vitro embryos the subjects of 
some form of limited legal protection characterized by the specific context of 
experimental medical research.  This determination could be made on the basis of some 
social interest, as opposed to an embryo’s individual interest, in conferring such 
protection.  Such a social interest can be found in the desire to protect the sanctity of 
[potential] human life.  Protecting the potential for human life is different from saying 
that a rights-bearing entity already exists.  By framing legislation in this way, such 
competing interests as women’s or patients’ rights can in some circumstances take 
priority over protecting an embryo.56  
Moreover, although the in vitro embryo exists as an independent entity, 
consideration needs to be given to the fact that the recognition of any embryonic rights 
will likely have indirect implications for female reproductive liberty.  For this reason, it 
may be inadvisable to introduce legislation that recognizes the embryo as a new legal 
individual with explicit rights. Such legislation can also outline and clarify certain duties 
that are owed to the embryo on a prima facie basis, but that can be overridden by other 
considerations.57  
B. Possible Scientific Harms of Stem Cell Research 
  In addition to the numerous social considerations implicated by stem cell research 
as discussed below, there are also health and safety considerations associated with the 
                                                 
55 Canada, House of Commons, Standing Committee on Health, “Assisted Human Reproduction:  Building 
Families” (December 2001) (Chair:  Bonnie Brown, M.P.) [hereinafter Building Families]. 
56 John A. Robertson, Reproductive Technology and Reproductive Rights:  In the Beginning:  The Legal 
Status of Early Embryos, 76 VA. L. REV. 437, 445-51 (1990). 
57 Parsi, supra note 8, at 705. 
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technology.  These may provide another basis for restrictive legislation.  Again, they will 
need to be balanced against the health benefits that this technology may provide. 
  It is now established that human embryos cannot remain frozen indefinitely 
without developing various abnormalities.  The longest time that a human embryo has 
been successfully cryopreserved is two years,58 though abnormalities may arise far 
sooner, even incidentally to the cryopreservation process.  Until some method exists to 
detect when and why these abnormalities occur, it may be dangerous to put stem cells 
derived from such embryos to medical use. 
  Also, while the purported value of stem cells lies in the fact that they are 
relatively undifferentiated, scientists still do not understand all the biological processes 
necessary to direct stem cells to specialize into desired cell and tissue types.  There is a 
risk that scientists may improperly signal the stem cells as they attempt to direct their 
specialization, leading to overgrowth.59 Such uncontrolled cell growth can lead to the 
development of a tumor, and is the hallmark of cancer.  Unsurprisingly, numerous animal 
studies have indeed identified increased rates of cancer among the recipients of stem cell-
derived tissue.  One of these studies, for example, showed that as much as three percent 
of mouse heart tissue that had been artificially cultured from stem cells became malignant 
after transplantation into mice.60  
  Concern has also been expressed about some of the specific practices that are 
employed in human stem cell research.  For example, many of the human stem cell 
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cultures that are created in the laboratory are nourished by animal cell cultures.  Mouse 
cells, for instance, are commonly used to help human stem cells replicate in vitro; bovine 
serum is also used to help in the derivation of specific colonies of human stem cells.61  
It is feared that such practices can lead to the transfer of animal viruses and other 
diseases into the human cells.  These viruses and diseases, in turn, could afflict any 
patients that are recipient to those stem cells.  Thus, legislation may be appropriate to 
protect Canadians from these medical risks, at least until such further time that they are 
either alleviated, or when scientific advances have lowered their probability. 
  C. Competing Rights 
       i)    Reproductive liberty rights: 
      One of the more obvious rights with which restrictions on embryo research may 
interfere, and that has already been frequently alluded to, is the right to reproductive 
liberty.  This becomes an issue particularly where restrictions are imposed on the basis of 
safeguarding the well-being of the embryo.  Simply put, “feminists are guarded about 
movements to accord rights to fetuses, since those rights are frequently invoked by those 
whose purpose is to regulate how women may behave when they are, or are liable to be, 
pregnant.”62 Some courts have been conscious of the linkage between banning embryo 
research and reproductive rights.  In Lifchez v. Hartigan, for example, a U.S. federal 
district court held that a law that banned certain forms of fetal research was 
unconstitutional on the grounds that it constituted an infringement upon reproductive 
liberty.63  
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One clear example of where conflict can arise is in a hypothetical case of a 
woman who decides to have an abortion to obtain access to stem cells that may help treat 
a disease-afflicted relative or friend.  It can be argued that a clear separation ought to be 
made between the decision to abort, and the decision to donate aborted embryonic or fetal 
tissue for medical uses.  It is unclear, however, if such a separation can be enforced.  To 
question the motives behind an abortion may in itself be viewed as an interference with 
the right to reproductive liberty.  Indeed, if abortion is considered to be a woman’s 
fundamental right, then its motive can be seen to be of secondary concern, or even 
irrelevant. 
Others might view restrictions on embryonic stem cell research, and on abortions 
carried out with the intent to benefit from such research, to be valid.  After all, these 
restrictions do not compel a woman to carry an embryo or fetus to term.  This line of 
reasoning would suggest that it is these negative procreative rights, i.e. rights that ensure 
bodily integrity, that constitute the essence of reproductive rights protections.  This 
attitude is reflected in some of the different laws in this field.  In the U.S., for example, 
researchers can legally use fetal tissue obtained from elective abortions only if those 
abortions were performed for reasons unrelated to the research.  Moreover, the National 
Institutes of Health Revitalization Act of 1993 specifically prohibits abortions with the 
intent to provide fetal tissue for transplant.64    
Typically, the option to donate is put forth to the patient only after she has made 
the decision to abort.  Moreover, the woman does not have the option to direct that the 
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donated tissue be used to benefit a particular person.65 These U.S. measures attempt to 
strike a balance between protecting women’s bodily integrity, and ensuring that an 
embryo/fetus is not created and/or terminated for research purposes.  Canada may very 
well choose to follow a similar approach. 
  Another interesting debate that arises in the context of reproductive rights deals 
with whether or not there is a right to avoid having biological offspring.  Some have 
pointed out, based on court cases dealing with contraception and other issues that such a 
right may exist.66 If true, then it is possible that any law that interferes with the discard, or 
that freely allows the donation of those in vitro embryos used in stem cell research, may 
violate that right.  This is because it would allow for the creation of biological offspring 
even where contrary to the wishes of one or both parents.  Perhaps such a right, if it 
exists, would be restricted to cases where the parent(s) would also be charged with the 
burden of rearing the child.67  
However, courts may consider that the mere knowledge that one has biological 
offspring somewhere would create a psychological burden that provides sufficient 
grounds for recognizing such a right.  At any rate, this issue is yet another of the many 
issues to be considered in drafting legislation pertaining to stem cell and embryo 
research. 
       ii)   Other competing rights: 
       Another potential right that may be infringed by restrictions on stem cell research 
is the right to conduct scientific research.  Such a right can possibly be read into section 
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2(b) of the Canadian Charter of Rights and Freedoms, which protects freedom of 
expression.  In R. v. Keegstra, the Supreme of Court of Canada stated quite clearly that 
“[a]t the core of freedom of expression lies the need to ensure that truth and the common 
good are attained, whether in scientific and artistic endeavors or in […] our political 
affairs [emphasis added].”68 Earlier, the U.S. Supreme Court had adopted a similar 
position in Miller v. California, stressing that “the courts must always remain sensitive to 
any infringement on genuinely serious literary, artistic, political, or scientific expression 
[emphasis added].”69
These statements recognize the public benefit that scientific inquiry provides, and 
the crucial role it plays in maintaining the sanctity of knowledge.  In keeping with this 
deference, Canadian courts appear to apply a primary presumption of liberty to pursue 
certain fields of scientific research.70  
One last collection of rights that may compete with restrictions on stem cell 
research are those belonging to Canadians afflicted with diseases that stem cell research 
may help treat or cure.  Indeed, some might see the treatment of these people as being a 
sufficient basis alone for permitting embryonic stem cell research.  Embryo research and 
practices that inevitably destroy some embryos are already permitted for treating one 
illness:  infertility.  As mentioned earlier, this is largely because fertility and the 
generation of offspring are seen as desirable goals on both an individual and a societal 
basis.  Can a similar desirability not be found in research that has the potential to cure 
debilitating diseases and save lives?  Indeed, if the reasons for protecting the embryo 
were to be based on the principle of respecting human life, then can this end not also be 
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achieved by helping improve the existing human lives of the thousands of disease-
afflicted Canadians? 
In fact, the life-threatening nature of many of these diseases suggests that 
Canadians may already have a constitutional right to stem cell therapies that are 
potentially life-saving.71 Such a right may be embodied in section 7 of the Charter, which 
protects one’s rights to “life, liberty and security of the person.”72 Section 15 of the 
Charter, which protects the equality rights of Canadians, may also be implicated.  To 
many disease-suffering Canadians, stem cell research may be one of the only means by 
which they can attain a level of comfort and dignity comparable to that enjoyed by 
healthy Canadians.  Indeed, “physical handicap” is one of the enumerated grounds of 
section 15 upon which an equality action can be raised.  Moreover, these disease sufferers 
can also be considered to be a historically disadvantaged group.  On account of their 
ailment, many have been denied the same opportunities in life that healthier Canadians 
have been able to enjoy.  A finding of such “historic disadvantage” would assist in 
determining whether or not this group’s section 15 rights would be violated.73  
  Moreover, government restrictions that, for example, prohibit public funding of 
research that leads to the destruction of an embryo may leave such research to be 
financed, and therefore controlled, by largely profit-seeking private companies.  This 
could restrict access to stem cell therapies to wealthy individuals, further widening the 
existing inequalities between rich and poor Canadians.74 Due consideration to all of these 
                                                 
71 Sina Muscati, Therapeutic Cloning and the Constitution – A Canadian Perspective, 8 HEALTH L. CAN. 
21 (2001). 
72 Canadian Charter of Rights and Freedoms, § 7, Part I of the Constitution Act, 1982, being Schedule B to 
the Canada Act 1982 (U.K.), 1982, ch. 11. 
73 See e.g. Law v. Canada (Minister of Employment and Immigration), [1999] 1 S.C.R. 497 at ¶ 39. 
74 Muscati, supra note 70. 
22  
competing rights will need to be given by the government when deciding what action to 
take regarding embryonic stem cell research. 
 D. Alternatives to Embryonic Stem Cell Research 
       Whether or not legal restrictions on embryonic stem cell research can be justified 
will depend partly on the availability of any real alternatives to it.  Where such 
alternatives exist, they would undermine any claims that embryonic stem cell research 
alone can lead to the medical advances desired.  This would make it even more difficult 
to justify the destruction of human embryos.  Thus, an analysis of these more morally-
unproblematic alternatives represents an alternate approach to evaluating embryonic stem 
cell research, one that side-steps the complex ethical debates, and focuses instead on 
whether such research is in fact necessary. 
   i)  Adult stem cell research: 
       Perhaps the most promising possible alternative to embryonic stem cell research 
is ongoing research into the use of adult stem cells.  As their name suggests, these cells 
exist in adult humans and share many of the properties of embryonic stem cells, including 
a low degree of differentiation.  Adult stem cells are found primarily in the bone marrow, 
brain, intestines and skin; they are also found in the placenta and umbilical cords of 
newborn babies.  Their main function is to repair the wear and tear that occurs in certain 
parts of the adult body.  For example, they help in renewing the intestinal lining, 
revitalizing and repairing skin and reproducing new blood cells by continuously 
specializing into new cells that replace older ones.75
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      It is hoped that adult stem cells can provide those same medical benefits that 
embryonic stem cells promise to provide.  Many, however, have been critical of just how 
beneficial adult stem cells can be.  They point out that such cells tend to be present in 
only minute quantities, and decrease in number with age.76 Adult stem cells are also 
difficult to purify and have yet to be isolated for every type of tissue.  Some research also 
suggests that adult stem cells may be able to divide only a limited number of times.77 
This would limit their use in creating sufficient numbers of specialized cells for medical 
application. 
       Despite such shortcomings, adult stem cell research has shown a lot of potential.  
Adult stem cells are being discovered for an increasing number of tissues, increasing the 
scope of their potential application.  New research also indicates that these cells are much 
more adaptable than once believed.  Scientists have encountered increasing success in 
specializing these cells into different tissue types as they begin to understand the 
chemical triggers that influence them.  Italian scientists, for example, have succeeded in 
triggering adult nerve stem cells that produce nerve cells in one location of the body to 
produce muscle cells in another.78  
      Other researchers have triggered adult bone marrow stem cells to develop into 
brain neurons.79 In August 2001, a team of Canadian researchers successfully 
transformed the adult skin stem cells of mice into various other cell-types, including brain 
cells, glial cells, muscle cells and fat cells.80  
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  Adult stem cells may also have certain advantages over their embryonic 
counterparts.  For example, the transfer of tissues derived from embryonic stem cells, 
unless cloned from the recipient, runs the same risks of immune rejection associated with 
transferring any foreign substance into the human body.  Such rejection can be treated 
only by a potentially lifelong prescription of anti-rejection drugs.  This problem is 
avoided in adult stem cells if they are obtained from the recipient him/herself such that 
they possess the same genetic makeup. 
      Adult stem cells have already been successfully used clinically, whereas 
embryonic stem cells have not.  In one case, a man suffering from scleromyxedema, a 
potentially fatal skin disease, was reportedly free of symptoms following a transplant of 
adult stem cells isolated from his own bone marrow.81 How much promise adult stem cell 
research shows will likely feature prominently in the debate over whether embryonic 
stem cell research can be justified. 
   ii)  Xenotransplantation and animal stem cell research: 
       Another field of research that may provide similar benefits to those promised by 
embryonic stem cell research involves the cross-species transplant of certain animal cells 
and tissues.  For example, rather than using embryonic stem cells to generate human 
organs, animal organs can be transplanted into humans, a process known as 
xenotransplantation, to address the current shortage of donated organs.  The transplant of 
animal organs runs the risk, again, of immune rejection in the human recipient.   
Scientists, however, are working to overcome this problem by the creation of 
transgenic animals.  These are animals that have been genetically altered by the direct 
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injection of genes from other species, namely humans, into the fertilized egg.  For 
example, the human body’s rejection of certain pig organs has already been partially 
overcome by creating transgenic pigs that express certain human regulatory proteins.82  
      Another ongoing field of research lies in the use of stem cells that contain human 
DNA, but are extracted from embryos derived from mammalian eggs.  Known as 
chimeras, these embryos are created by transferring the nucleus of a human cell (where 
nearly all DNA exists) to a mammalian egg cell whose nucleus has been removed.  The 
procedure, known as somatic cell nuclear transfer, is the same procedure used in whole-
organism cloning (in creating Dolly the sheep, for example).  Because they are cloned, 
the derivative stem cells have the added benefit of providing an exact genetic match for 
the recipient.  The procedure also has practical advantages, given the ample supply of 
mammalian eggs compared to human eggs.  Scientists have already succeeded in using 
cow and pig eggs to create cow/human and pig/human chimeras.  The embryos undergo a 
few cleavages, although they are still non-viable in the long-term.83  
       The use of chimeric embryos might side-step some of the ethical concerns 
associated with experimenting on human embryos.  This is because chimeric embryos are 
technically not human, given that their cellular composition includes both human and 
animal components.  However, the creation of chimeric embryos raises ethical issues 
relating to the mixing of human DNA and other cellular components with that of other 
species.  Indeed, there is widespread concern that this practice represents an affront to 
human dignity.  There are also safety concerns that arise when the biological products of 
another species are incorporated into the human body.  Hence, it is unclear if the use of 
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chimeric embryos provides a truly viable alternative to human embryonic stem cell 
research. 
  iii)  Other alternatives: 
       It was recently discovered that some of the stem cells found in fetuses can be as 
valuable for research as embryonic stem cells.  For example, fetal bone marrow stem 
cells have been discovered to be highly adaptable, provoking low rates of immune 
rejection.84
      Another valuable group of cells, known as embryonic germ cells, are also found 
in fetuses.  These cells are destined to specialize into the eggs or sperm of the future 
adult.85 They too have properties resembling those of embryonic stem cells.  Fetal cells 
can even be isolated from spontaneously aborted or stillborn fetuses, again side-stepping 
the ethical concerns associated with the deliberate destruction of human embryos.  
       Other scientific breakthroughs are also promising new alternatives to embryonic 
stem cell research.  For example, PPL Therapeutics, the same firm that cloned Dolly the 
sheep, is working on a method of converting ordinary cells into stem cells through a 
process known as de-differentiation.86  
      If successful, then ordinary cells may replace embryos as a primary source of 
stem cells.  Also, a team of Canadian scientists has recently discovered a means to make 
non-embryonic stem cells reproduce in vitro as rapidly as embryonic stem cells.87 This 
development will greatly facilitate research on developing alternatives to embryonic stem 
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cells, as well as on the creation and maintenance of non-embryonic stem cell cultures for 
clinical use. 
Part IV. The Canadian Legal Response to Stem Cell Research 
 A. The History of Legal Measures Against Reproductive and Genetic 
Technologies 
      The law in Canada pertaining to embryonic stem cell research is currently 
unclear.  In 1989, the federal government established the Royal Commission on New 
Reproductive Technologies, which released its 1200 page final report in 1993.  That 
report set out a number of recommendations, including the passage of laws to govern 
various reproductive technologies, and criminal prohibitions against specific activities 
that “conflict…sharply with the values espoused by Canadians, and are…potentially 
harmful to the interests of individuals and of society […].”88 In response, the Minister of 
Health issued a voluntary moratorium in July 1995 against nine reproductive 
technologies.89 These included the cloning of human embryos, the formation of animal-
human hybrids and the creation of an artificial womb.90
      In 1996, Bill C-47 (The Human Reproductive and Genetic Technologies Act) was 
introduced into the House of Commons, and passed first reading.  The bill set out 
criminal prohibitions against a number of practices, including human cloning, sex 
selection and the selling of genetic material.91  
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However, it was terminated after Parliament was dissolved following the federal election 
call of 1997.  Later that year, Bill C-247 was introduced to ban human cloning.  That bill 
was defeated following its second reading in the House of Commons.  All this has left 
Canada without any legislation governing reproductive and genetic technologies 
Proposed Canadian Legislation 
The federal government recently revived attempts to pass new legislation 
governing reproductive and genetic technologies.  Draft legislation (The Assisted Human 
Reproduction Act) was drawn up in May 2001, and tabled in the House of Commons as 
Bill C-56 in May 2002.  The Bill proposes, again, complete prohibitions of various 
controversial research practices.  These include the cloning of humans, the development 
of an in vitro embryo beyond fourteen days, the creation of embryos solely for research 
purposes and the use of human reproductive material previously transplanted into an 
animal.92 The Bill also proposes that other, less controversial activities, be controlled by 
regulation.  These measures are consistent with the proposals of the Canadian Institutes 
for Health Research (CIHR) regarding stem cell research.93  
Earlier, in December 2001, the Standing Committee on Health had issued a report 
following its review of the draft legislation.  It called for an even tougher set of laws than 
those proposed.  The Standing Committee also noted that it was “struck by […the] 
tremendous gains in adult stem cell research in humans,” recommending that no licence 
to experiment on surplus embryos be issued “unless the applicant clearly demonstrates 
                                                 
92 Bill C-56, An Act respecting assisted human reproduction, 1st Sess., 37th Parl., 2002, cl. 5(1) (1st 
reading 9 May 2002). 
93 Id. 
29  
that no other category of biological material could be used for the purposes of the 
proposed research.”94  
Further, it recommended the development of “regulated standards in relation to 
the maximum number of embryos that may be produced, stored and transferred for in 
vitro fertilization procedures,” as well as a prohibition on creating surplus embryos “once 
egg-storage techniques have been perfected and validated.”95 Bill C-56 will be subject to 
further review and its passage is expected to take several months.  Several more months 
will be needed before any new regulatory body could begin to function. 
Many aspects of the Bill and the Standing Committee’s proposals are interesting.  
For example, they appear to recognize a moral distinction between embryos that are and 
are not created for research purposes.  They also distinguish between embryos that are 
older and younger than fourteen days.  The proposed requirement of having researchers 
demonstrate the necessity of experimenting on embryos is also significant.  Clearly, this 
would give new importance to the many potential alternatives to embryonic stem cell 
research that were outlined earlier.  
  B. Comparing Proposed Canadian Measures to Those of Other Nations 
      The passage of Bill C-56 would make Canada the newest in a long list of nations 
to adopt measures intended to govern stem cell research.  Some, including the United 
Kingdom, France, Germany and Japan have already passed laws and in some cases set up 
governing bodies to deal with genetic technologies.96  
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 Specific measures, such as the fourteen-day limit on embryo research, would place 
Canada in a similar position to other countries, such as the U.K., which has adopted this 
same limit.  The proposal to allow the use of surplus embryos also goes much further 
than the measures taken in other countries.  In the United States, for example, President 
Bush announced in August 2001 that federal funding of stem cell research would be 
allowed only on existing embryonic stem cell cultures, where the decision to terminate 
the embryos had already been made. 
  The divergence from the U.S. position has some advantages.  It avoids the 
seeming paradox of not funding research that creates embryonic stem cell cultures, but 
then funding research on those same cultures after they have been derived without the 
observance of any regulatory or ethical standards.97 Access to existing embryonic stem 
cell cultures may also be restricted given that they are subject to private patent protection.  
Some groups, such as the U.S. National Academy of Sciences, have also suggested that 
the therapeutic potential of stem cell research can only be exploited if research is 
expanded beyond existing stem cell cultures.98  
  C. Critiques of the Proposals 
  i)  Ambiguity and the problem posed by rapid scientific advances: 
      One of the most striking problems in the proposed legislation is that it is 
potentially ambiguous with respect to some of the scientific terms and processes 
described.  Many of the phrases used, such as “alter the genome,” are difficult to 
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interpret.  It is unclear, for instance, whether this phrase refers to all the DNA, or only 
parts of it.  Would it encompass a change that affects a single DNA base pair, which 
represents one molecule out of approximately six billion?  These are important 
determinations that will need to be made. 
     Another example is that while the text of Bill C-56 appears to renounce the idea of 
creating an animal/human hybrid, it is ambiguous as to whether the creation of those 
chimeric clones described earlier in the paper is absolutely prohibited.  The legislation 
defines a chimera as a human embryo “into which a cell of any non-human life form has 
been introduced” or “that consists of cells of more than one embryo, fetus, or human 
being.”99 This definition would not include chimeric clones.  They may be encompassed 
by the prohibition against creating human clones, defined as an embryo with the same 
nuclear DNA sequence as another human organism.  However, an embryo is defined as a 
human organism, and it is unclear if embryos with cells having human nuclei but animal 
cellular components can be considered as such.  The Standing Committee also found 
problems with the definitions provided for “gene,” “genome,” “embryo” and “embryo 
donor.”100 Clearly, there may be a need for further clarity in the Bill. 
     The proposed legislation also may fall quickly out-of-touch with both the priorities of 
Canadians and the state of reproductive and genetic technologies, given the rapid pace of 
scientific developments in this area.  For example, one of the motivations behind banning 
such practices as the therapeutic cloning of embryos is the human health and safety risks 
that are posed by this technology in its current state.  Further technological advances, 
however, may eliminate many of these risks, at which time it may be appropriate to de-
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criminalize such practices.  To do so, however, would require legislative amendments, 
which involve a complex and time-consuming process.  Indeed, the Standing Committee 
acknowledged that there exists a “rapidly changing scientific and technological 
environment,” and recommended parliamentary review of any legislation within three 
years.101 Such a provision was adopted in Bill C-56;102 however, a lot of significant 
changes can occur even within three years. This brings to question the appropriateness of 
using criminal law in trying to control scientific fields as dynamic as biotechnology. 
  
 ii) The problems with a criminal law approach: 
      Just as new scientific developments may eliminate certain risks, other developments 
can give rise to new social issues or concerns that were unforeseeable just a short while 
before.  This means that the scientific fields at issue will need to be revisited constantly.  
However, as has been shown, it is impractical to do so with criminal legislation.103 
Indeed, it is quite likely that if and when Bill C-56 finally passes into law, new issues will 
have arisen that, while requiring attention, had not been anticipated.  An additional 
concern with criminal legislation is that police, who play a prominent role in enforcing 
criminal law, have little experience with human reproductive and genetic technologies.   
  What are the alternatives to criminal law?  Two of Canada’s prominent health law 
experts, Bartha M. Knoppers and Timothy Caulfield, have suggested the creation of a 
comprehensive regulatory scheme.  This scheme would establish effective control over 
controversial scientific practices but still be flexible enough to accommodate scientific 
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developments and changing social priorities.104 The suggested scheme could perhaps 
consist of an expanded version of the regulatory regime already contemplated by Bill C-
56.  In fact, some of the expert witnesses who appeared before the Standing Committee, 
citing the benefits of regulatory flexibility, recommended the elimination of the 
prohibited activities category altogether.105 With a regulatory scheme in place, desired 
amendments could be achieved more quickly through the usual process for amending 
regulations, rather than through legislative changes. 
  
Part V. Conclusion 
Research on embryonic stem cells has emerged as one of the more controversial 
areas of medical science.  While the medical benefits of the research look promising, the 
ethical dilemmas of embryo research and destruction remain.  Capitalizing on the benefits 
of stem cell research will require a clarification of the legal status of the embryo and the 
adoption of clear ethical standards and guidelines. 
  Canadian jurisprudence currently deems unborn children to be prenatal entities 
with rights that remain inchoate until birth.  It is not clear, however, how the law will 
treat the in vitro embryo, which has an independent physical existence.  The courts have 
recognized a parliamentary right to legislate on behalf of the embryo in well-defined 
circumstances.  Draft legislation has now been introduced to limit reproductive and 
genetic technologies. 
  Any future legislation must remain cognizant of a number of concerns.  
Applications of stem cell therapies, due to the primitive state of the technology as well as 
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the nature of the biological processes involved, have numerous safety risks.  Canadians 
need to be protected against these.  Legislating protections to the embryo can also 
indirectly affect female reproductive autonomy, a fact that needs to be addressed.  Other 
rights will also need to be balanced, including any right to scientific research, and the 
rights of disease-afflicted Canadians to benefit from stem cell therapies.  Finally, 
scientific advances in other fields of biotechnology, such as adult stem cell research, may 
provide similar benefits to embryonic stem cell research in less morally controversial 
ways.  The significance of these advances will need to be recognized.   
While Canada’s draft legislation goes some way to addressing these issues, 
certain ambiguities within it suggest that Parliament may not yet have a full 
understanding or appreciation of this complex technology.  Moreover, the use of criminal 
law may be too rigid a mechanism to apply to this dynamic field.  The important ethical, 
health and social issues that embryonic stem cell research gives rise to make it critical for 
Canada to establish an effective policy with respect to this technology.  With a proper 
dialogue between scientists, ethicists and jurists, such a policy hopefully will not only be 
conducive to medical progress, but will also address the legitimate ethical and legal 
concerns of the Canadian public. 
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